Biomarkers in immuno-oncology

First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Interim Results From the Phase 3 KEYNOTE-048 Study

Updates on NETs and endocrine tumours

Clinical implementation of PI3K inhibitors

Targeted therapy and EGFR mutations

Highlitghs of ESMO - IO and targeted therapy in lung cancer

Two illustrative and interactive tumour board style case study discussions

Update on the latest clinical practice referring to NETs

New results in Head and Neck Cancer

Biomarkes in Immuno-Oncology (PDL-1 testing)

How to manage pretreated mCRC patients: An expert’s approach

IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab + nab-paclitaxel vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer IMPassion130

Overall survival with palbociclib plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analyses from PALOMA-3

Alpelisib + fulvestrant for advanced breast cancer: results of the Phase III SOLAR-1 trial

IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab + nab-paclitaxel vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer IMPassion130

Use of immune checkpoint inhibitors in early stage NSCLC – Next generation trials in NSCLC